Immunovant (IMVT) Retained Earnings (2018 - 2026)

Immunovant (IMVT) has 9 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.

• Quarterly Retained Earnings fell 119709.32% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 119709.32% YoY) and the FY2026 annual result came in at -$1.7 billion, down 119709.32% from the prior year.
• Retained Earnings retreated to -$1.7 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $2.0 billion in Q3 2025 to a low of -$1.7 billion in Q1 2026.
• A 5-year average of -$315.5 million and a median of -$355.4 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings surged 357344.87% — and 2024, when it sank 199310.92%.
• Tracing IMVT's Retained Earnings over 5 years: stood at $920.2 million in 2022, then tumbled by 181.54% to -$750.4 million in 2023, then plunged by 51.0% to -$1.1 billion in 2024, then sank by 40.97% to -$1.6 billion in 2025, then declined by 9.25% to -$1.7 billion in 2026.
• The last three Retained Earnings figures came in at -$1.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.